Method
Level · gp.fundamentals.debt_to_revenue
Raw value 287.23% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTARS Pharmaceuticals, Inc.'s latest supported as-filed period reports revenue of $33.7M, 114.2% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 287.23% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -181.02% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 114.15% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 91.31% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -182.62% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 114.2%; Operating margin moved 12033 bp higher; Operating income decreased 29.1%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 114.2%; Operating margin moved 12033 bp higher; Operating income decreased 29.1%.
3 evidence-backed componentsStock-based compensation changed +130.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
SPRY · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0002149973-26-000004SEC ↗10-QAug 13, 2026Period Jun 30, 20260001193125-26-349140SEC ↗8-KAug 13, 2026Period Aug 13, 20260001193125-26-349127SEC ↗8-KJul 17, 2026Period Jul 15, 20260001193125-26-307773SEC ↗8-KJul 7, 2026Period Jul 6, 20260001193125-26-297554SEC ↗4Jul 2, 2026Period Jul 1, 20260002135296-26-000007SEC ↗4Jun 26, 2026Period Jun 24, 20260001231919-26-000704SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 13.96% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 36.83% · OPTIONAL
Operating income changed -29.1% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Net income changed -38.9% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Operating margin changed +12033 basis points from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Revenue changed +114.2% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Cash & equivalents changed -84.2% from the comparable as-filed period.
Inventory / revenue changed -4938 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-285521